| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 47 | 2021 | 1074 | 1.920 |
Why?
|
| Lung Neoplasms | 55 | 2023 | 2261 | 1.730 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 43 | 2021 | 2436 | 1.270 |
Why?
|
| Advisory Committees | 1 | 2022 | 90 | 0.850 |
Why?
|
| Medical Oncology | 1 | 2022 | 359 | 0.670 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 3 | 2009 | 14 | 0.660 |
Why?
|
| Vinblastine | 13 | 2002 | 108 | 0.590 |
Why?
|
| Paclitaxel | 15 | 2008 | 460 | 0.560 |
Why?
|
| Ifosfamide | 12 | 2003 | 49 | 0.480 |
Why?
|
| Combined Modality Therapy | 26 | 2010 | 1685 | 0.430 |
Why?
|
| Esophageal Neoplasms | 7 | 2010 | 321 | 0.400 |
Why?
|
| Survival Rate | 22 | 2021 | 1860 | 0.360 |
Why?
|
| Cisplatin | 15 | 2010 | 612 | 0.350 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2019 | 1075 | 0.350 |
Why?
|
| Antineoplastic Agents | 12 | 2019 | 2357 | 0.340 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 13 | 2008 | 165 | 0.330 |
Why?
|
| Adenocarcinoma | 11 | 2012 | 1169 | 0.320 |
Why?
|
| Antineoplastic Agents, Phytogenic | 8 | 2008 | 276 | 0.310 |
Why?
|
| Camptothecin | 4 | 2008 | 189 | 0.300 |
Why?
|
| Neoplasm Staging | 22 | 2019 | 1937 | 0.300 |
Why?
|
| Aged | 52 | 2021 | 18402 | 0.290 |
Why?
|
| Nucleosides | 1 | 2006 | 22 | 0.280 |
Why?
|
| Biomarkers, Tumor | 4 | 2023 | 1464 | 0.280 |
Why?
|
| Middle Aged | 54 | 2021 | 25017 | 0.260 |
Why?
|
| Carcinoma, Small Cell | 3 | 2004 | 134 | 0.250 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2020 | 236 | 0.240 |
Why?
|
| Humans | 72 | 2023 | 86601 | 0.220 |
Why?
|
| Adult | 48 | 2021 | 25640 | 0.220 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 127 | 0.210 |
Why?
|
| Female | 58 | 2021 | 44507 | 0.210 |
Why?
|
| Male | 56 | 2021 | 40956 | 0.200 |
Why?
|
| Carboplatin | 8 | 2008 | 286 | 0.200 |
Why?
|
| Taxoids | 7 | 2012 | 129 | 0.200 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 42 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 104 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2008 | 1961 | 0.190 |
Why?
|
| Salvage Therapy | 2 | 2019 | 233 | 0.180 |
Why?
|
| Capecitabine | 1 | 2020 | 96 | 0.180 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 19 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 592 | 0.180 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 3636 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 1998 | 138 | 0.180 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 23 | 0.180 |
Why?
|
| Remission Induction | 10 | 2011 | 722 | 0.170 |
Why?
|
| Infusions, Intravenous | 5 | 2002 | 429 | 0.170 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 6501 | 0.170 |
Why?
|
| Treatment Outcome | 17 | 2014 | 7988 | 0.160 |
Why?
|
| Benzamides | 1 | 2019 | 229 | 0.160 |
Why?
|
| Pyrazoles | 1 | 2019 | 153 | 0.160 |
Why?
|
| Radiosurgery | 1 | 2021 | 272 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 199 | 0.160 |
Why?
|
| Blood Group Incompatibility | 2 | 2009 | 18 | 0.160 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2015 | 90 | 0.150 |
Why?
|
| Piperazines | 1 | 2019 | 272 | 0.150 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 266 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2012 | 1313 | 0.140 |
Why?
|
| Pneumonectomy | 4 | 2011 | 196 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2021 | 629 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 589 | 0.140 |
Why?
|
| Prognosis | 9 | 2021 | 3674 | 0.130 |
Why?
|
| Interferon-alpha | 4 | 1997 | 233 | 0.130 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 2887 | 0.130 |
Why?
|
| Carcinoma | 1 | 1998 | 436 | 0.130 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2012 | 56 | 0.130 |
Why?
|
| Fluorouracil | 9 | 1998 | 556 | 0.120 |
Why?
|
| Mesna | 2 | 2008 | 9 | 0.120 |
Why?
|
| Exanthema | 1 | 2014 | 36 | 0.120 |
Why?
|
| Disease Progression | 6 | 2023 | 1531 | 0.120 |
Why?
|
| Drug Administration Schedule | 12 | 2003 | 916 | 0.120 |
Why?
|
| Blood Proteins | 1 | 2014 | 144 | 0.120 |
Why?
|
| Leucovorin | 8 | 1998 | 218 | 0.110 |
Why?
|
| Organoplatinum Compounds | 2 | 2004 | 94 | 0.110 |
Why?
|
| Ketones | 1 | 2012 | 13 | 0.110 |
Why?
|
| Furans | 1 | 2012 | 16 | 0.110 |
Why?
|
| Proteomics | 1 | 2014 | 212 | 0.110 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 39 | 0.100 |
Why?
|
| Glutamates | 2 | 2014 | 89 | 0.100 |
Why?
|
| United States | 2 | 2022 | 6665 | 0.100 |
Why?
|
| Guanine | 2 | 2014 | 208 | 0.100 |
Why?
|
| Sirolimus | 1 | 2012 | 169 | 0.090 |
Why?
|
| Recombinant Proteins | 6 | 2008 | 1014 | 0.090 |
Why?
|
| Thigh | 1 | 1990 | 38 | 0.090 |
Why?
|
| Neutropenia | 6 | 2008 | 215 | 0.090 |
Why?
|
| ErbB Receptors | 4 | 2015 | 485 | 0.090 |
Why?
|
| Transfusion Reaction | 1 | 2009 | 15 | 0.090 |
Why?
|
| Cladribine | 1 | 2009 | 35 | 0.090 |
Why?
|
| Splenectomy | 1 | 2009 | 82 | 0.080 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 64 | 0.080 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1990 | 126 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 78 | 0.080 |
Why?
|
| Transplantation | 1 | 2009 | 39 | 0.080 |
Why?
|
| Vidarabine | 1 | 2009 | 141 | 0.080 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2009 | 66 | 0.080 |
Why?
|
| Rituximab | 1 | 2009 | 116 | 0.080 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 107 | 0.080 |
Why?
|
| Erythropoietin | 1 | 2008 | 91 | 0.080 |
Why?
|
| Survival Analysis | 7 | 2011 | 1538 | 0.080 |
Why?
|
| Drug Tolerance | 3 | 1996 | 63 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 263 | 0.080 |
Why?
|
| Quinazolines | 1 | 2008 | 220 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2011 | 395 | 0.070 |
Why?
|
| Thoracic Neoplasms | 2 | 1998 | 64 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 996 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2009 | 153 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2007 | 334 | 0.070 |
Why?
|
| Histocompatibility | 1 | 2006 | 71 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2006 | 70 | 0.070 |
Why?
|
| Dacarbazine | 1 | 2006 | 102 | 0.070 |
Why?
|
| Filgrastim | 3 | 2008 | 56 | 0.060 |
Why?
|
| Mutation | 4 | 2023 | 3967 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2008 | 751 | 0.060 |
Why?
|
| Radiotherapy Dosage | 4 | 2001 | 468 | 0.060 |
Why?
|
| Gene Amplification | 2 | 2019 | 131 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2014 | 1204 | 0.060 |
Why?
|
| Neoplasms | 3 | 1997 | 2897 | 0.060 |
Why?
|
| Thionucleotides | 1 | 2004 | 56 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2008 | 763 | 0.060 |
Why?
|
| Cephalexin | 1 | 2003 | 6 | 0.060 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2003 | 16 | 0.060 |
Why?
|
| Etoposide | 4 | 2008 | 196 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 977 | 0.060 |
Why?
|
| Survival | 1 | 2002 | 21 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 189 | 0.060 |
Why?
|
| Time Factors | 3 | 2014 | 5209 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1376 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 4 | 2008 | 270 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2006 | 329 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 878 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 58 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 33 | 0.050 |
Why?
|
| Pemetrexed | 2 | 2014 | 76 | 0.050 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 26 | 0.050 |
Why?
|
| Retrospective Studies | 6 | 2021 | 8475 | 0.050 |
Why?
|
| Ceftizoxime | 1 | 1999 | 3 | 0.050 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1999 | 6 | 0.040 |
Why?
|
| North America | 1 | 2000 | 180 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 1999 | 12 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1999 | 24 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 1999 | 36 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 456 | 0.040 |
Why?
|
| Europe | 1 | 2000 | 309 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 468 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1161 | 0.040 |
Why?
|
| Agranulocytosis | 2 | 1995 | 20 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2009 | 2207 | 0.040 |
Why?
|
| Topotecan | 1 | 1998 | 45 | 0.040 |
Why?
|
| Macrolides | 2 | 2012 | 31 | 0.040 |
Why?
|
| Chemoradiotherapy | 2 | 2011 | 301 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 746 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 4210 | 0.040 |
Why?
|
| Esophagus | 1 | 1998 | 102 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 1995 | 176 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 329 | 0.040 |
Why?
|
| Neoplasm Metastasis | 3 | 2012 | 1056 | 0.040 |
Why?
|
| Expectorants | 1 | 1996 | 6 | 0.040 |
Why?
|
| Chicago | 3 | 2014 | 1379 | 0.040 |
Why?
|
| International Agencies | 1 | 2015 | 34 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1996 | 94 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 244 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1850 | 0.030 |
Why?
|
| Bone Marrow | 4 | 1998 | 435 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 1994 | 17 | 0.030 |
Why?
|
| Cetuximab | 1 | 2014 | 113 | 0.030 |
Why?
|
| Hydroxyurea | 4 | 1995 | 239 | 0.030 |
Why?
|
| Esophagitis | 3 | 1998 | 42 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 481 | 0.030 |
Why?
|
| Ethers, Cyclic | 1 | 2012 | 7 | 0.030 |
Why?
|
| Bridged-Ring Compounds | 1 | 2012 | 13 | 0.030 |
Why?
|
| Indoles | 1 | 1994 | 318 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 1583 | 0.030 |
Why?
|
| Platinum | 1 | 2012 | 63 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2356 | 0.030 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2011 | 18 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 860 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2003 | 229 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1823 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 96 | 0.020 |
Why?
|
| Administration, Oral | 3 | 2001 | 684 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 128 | 0.020 |
Why?
|
| Whole-Body Counting | 1 | 1989 | 7 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1989 | 32 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 199 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1673 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2007 | 2767 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2008 | 5 | 0.020 |
Why?
|
| Hematinics | 1 | 2008 | 11 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 20 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 930 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1989 | 286 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 5416 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 348 | 0.020 |
Why?
|
| Anemia | 1 | 2008 | 128 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1990 | 261 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2007 | 31 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1718 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 363 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 894 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1204 | 0.020 |
Why?
|
| Cyclophosphamide | 3 | 1992 | 299 | 0.020 |
Why?
|
| Leukemia | 1 | 1987 | 320 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2007 | 328 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 317 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 69 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 5974 | 0.010 |
Why?
|
| Bryostatins | 1 | 2003 | 15 | 0.010 |
Why?
|
| Lactones | 1 | 2003 | 28 | 0.010 |
Why?
|
| Premedication | 1 | 2003 | 54 | 0.010 |
Why?
|
| Sex Factors | 2 | 2000 | 1054 | 0.010 |
Why?
|
| Smoking | 2 | 2000 | 609 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 256 | 0.010 |
Why?
|
| Lung | 1 | 1987 | 1170 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2001 | 79 | 0.010 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 21 | 0.010 |
Why?
|
| Methotrexate | 2 | 1992 | 249 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1998 | 1169 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2003 | 352 | 0.010 |
Why?
|
| Doxorubicin | 2 | 1992 | 295 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1990 | 141 | 0.010 |
Why?
|
| Spirometry | 1 | 2000 | 66 | 0.010 |
Why?
|
| Coombs Test | 1 | 1999 | 8 | 0.010 |
Why?
|
| Creatinine | 1 | 2001 | 338 | 0.010 |
Why?
|
| Pilot Projects | 2 | 1994 | 839 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2000 | 122 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 61 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1999 | 87 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1989 | 2600 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 683 | 0.010 |
Why?
|
| Platelet Count | 1 | 1999 | 92 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1999 | 114 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 350 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 75 | 0.010 |
Why?
|
| Isotretinoin | 1 | 1997 | 23 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1999 | 292 | 0.010 |
Why?
|
| Antidotes | 1 | 1997 | 23 | 0.010 |
Why?
|
| Leukopenia | 1 | 1997 | 65 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1997 | 117 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1998 | 596 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1997 | 227 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 1195 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1997 | 303 | 0.010 |
Why?
|
| Incidence | 1 | 2000 | 1576 | 0.010 |
Why?
|
| Esophagogastric Junction | 1 | 1995 | 34 | 0.010 |
Why?
|
| Age Factors | 1 | 2000 | 1849 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1996 | 155 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 1753 | 0.010 |
Why?
|
| Cyclohexenes | 1 | 1994 | 5 | 0.010 |
Why?
|
| Benzofurans | 1 | 1994 | 8 | 0.010 |
Why?
|
| Palliative Care | 1 | 1996 | 257 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1995 | 291 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1994 | 79 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1995 | 221 | 0.010 |
Why?
|
| Research Design | 1 | 1997 | 594 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1995 | 183 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1994 | 155 | 0.010 |
Why?
|
| Procarbazine | 1 | 1992 | 40 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 1994 | 170 | 0.010 |
Why?
|
| Vincristine | 1 | 1990 | 111 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1994 | 864 | 0.010 |
Why?
|
| Bleomycin | 1 | 1990 | 98 | 0.010 |
Why?
|
| Vindesine | 1 | 1989 | 9 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1990 | 364 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1989 | 49 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 1989 | 46 | 0.010 |
Why?
|
| Cytarabine | 1 | 1990 | 218 | 0.010 |
Why?
|
| Radiography, Abdominal | 1 | 1989 | 71 | 0.010 |
Why?
|
| Prednisone | 1 | 1990 | 258 | 0.010 |
Why?
|
| Thiotepa | 1 | 1989 | 32 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1989 | 220 | 0.010 |
Why?
|
| Melphalan | 1 | 1989 | 97 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1987 | 66 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 1990 | 857 | 0.000 |
Why?
|
| Karyotyping | 1 | 1987 | 250 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1990 | 999 | 0.000 |
Why?
|
| Radiography, Thoracic | 1 | 1989 | 320 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1989 | 394 | 0.000 |
Why?
|
| Acute Disease | 1 | 1987 | 826 | 0.000 |
Why?
|